These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 34745006)

  • 1. Effects of SGLT2 Inhibitors and GLP-1 Receptor Agonists on Renin-Angiotensin-Aldosterone System.
    Puglisi S; Rossini A; Poli R; Dughera F; Pia A; Terzolo M; Reimondo G
    Front Endocrinol (Lausanne); 2021; 12():738848. PubMed ID: 34745006
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SGLT2 inhibition effect on salt-induced hypertension, RAAS, and Na
    Kravtsova O; Bohovyk R; Levchenko V; Palygin O; Klemens CA; Rieg T; Staruschenko A
    Am J Physiol Renal Physiol; 2022 Jun; 322(6):F692-F707. PubMed ID: 35466690
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Benefits and harms of sodium-glucose co-transporter-2 inhibitors (SGLT2-I) and renin-angiotensin-aldosterone system inhibitors (RAAS-I) versus SGLT2-Is alone in patients with type 2 diabetes: A systematic review and meta-analysis of randomized controlled trials.
    Seidu S; Kunutsor SK; Topsever P; Khunti K
    Endocrinol Diabetes Metab; 2022 Jan; 5(1):e00303. PubMed ID: 34636161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of sodium-glucose cotransporter-2 inhibitors on aldosterone-to-renin ratio in diabetic patients with hypertension: a retrospective observational study.
    Sawamura T; Karashima S; Nagase S; Nambo H; Shimizu E; Higashitani T; Aono D; Ohbatake A; Kometani M; Demura M; Furukawa K; Takeda Y; Yoneda T
    BMC Endocr Disord; 2020 Nov; 20(1):177. PubMed ID: 33256676
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diuretic Effects of Sodium Glucose Cotransporter 2 Inhibitors and Their Influence on the Renin-Angiotensin System.
    Ansary TM; Nakano D; Nishiyama A
    Int J Mol Sci; 2019 Feb; 20(3):. PubMed ID: 30717173
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SGLT2 inhibitors: a novel choice for the combination therapy in diabetic kidney disease.
    Zou H; Zhou B; Xu G
    Cardiovasc Diabetol; 2017 May; 16(1):65. PubMed ID: 28511711
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Strategies for Appropriate Selection of SGLT2-i vs. GLP1-RA in Persons with Diabetes and Cardiovascular Disease.
    Dhindsa DS; Mehta A; Sandesara PB; Thobani A; Brandt S; Sperling LS
    Curr Cardiol Rep; 2019 Jul; 21(9):100. PubMed ID: 31352613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of a 3-Week Treatment with GLP-1 Receptor Agonists on Vasoactive Hormones in Euvolemic Participants.
    Vukajlovic T; Sailer CO; Asmar A; Jensen BL; Vogt DR; Christ-Crain M; Winzeler B
    J Clin Endocrinol Metab; 2022 May; 107(6):e2581-e2589. PubMed ID: 35134170
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How Do SGLT2 (Sodium-Glucose Cotransporter 2) Inhibitors and GLP-1 (Glucagon-Like Peptide-1) Receptor Agonists Reduce Cardiovascular Outcomes?: Completed and Ongoing Mechanistic Trials.
    Lee MMY; Petrie MC; McMurray JJV; Sattar N
    Arterioscler Thromb Vasc Biol; 2020 Mar; 40(3):506-522. PubMed ID: 31996025
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The potential and pitfalls of GLP-1 receptor agonists for renal protection in type 2 diabetes.
    Thomas MC
    Diabetes Metab; 2017 Apr; 43 Suppl 1():2S20-2S27. PubMed ID: 28431667
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of sodium-glucose co-transporter-2 inhibitors or glucagon-like peptide-1 receptor agonists versus sulfonylureas and the risk of lower limb amputations: a nation-wide cohort study.
    Werkman NCC; Driessen JHM; Stehouwer CDA; Vestergaard P; Schaper NC; van den Bergh JP; Nielen JTH
    Cardiovasc Diabetol; 2023 Jun; 22(1):160. PubMed ID: 37386427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sodium-glucose cotransporter 2 inhibitors and renin-angiotensin-aldosterone system, possible cellular interactions and benefits.
    Forouzanmehr B; Hedayati AH; Gholami E; Hemmati MA; Maleki M; Butler AE; Jamialahmadi T; Kesharwani P; Yaribeygi H; Sahebkar A
    Cell Signal; 2024 Oct; 122():111335. PubMed ID: 39117253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The protective effects of SGLT-2 inhibitors, GLP-1 receptor agonists, and RAAS blockers against renal injury in patients with type 2 diabetes.
    Kuang Z; Hou N; Kan C; Han F; Qiu H; Sun X
    Int Urol Nephrol; 2023 Mar; 55(3):617-629. PubMed ID: 36036316
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes.
    Cardoso P; Young KG; Nair ATN; Hopkins R; McGovern AP; Haider E; Karunaratne P; Donnelly L; Mateen BA; Sattar N; Holman RR; Bowden J; Hattersley AT; Pearson ER; Jones AG; Shields BM; McKinley TJ; Dennis JM;
    Diabetologia; 2024 May; 67(5):822-836. PubMed ID: 38388753
    [TBL] [Abstract][Full Text] [Related]  

  • 15. SGLT2 inhibitors and cardioprotection: a matter of debate and multiple hypotheses.
    Filippatos TD; Liontos A; Papakitsou I; Elisaf MS
    Postgrad Med; 2019 Mar; 131(2):82-88. PubMed ID: 30757937
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Relationship between urinary sodium excretion and serum aldosterone in patients with diabetes in the presence and absence of modifiers of the renin-angiotensin-aldosterone system.
    Libianto R; Jerums G; Lam Q; Chen A; Baqar S; Pyrlis F; Macisaac RJ; Moran J; Ekinci EI
    Clin Sci (Lond); 2014 Jan; 126(2):147-54. PubMed ID: 23875766
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Beta-adrenergic receptor blockade as a therapeutic approach for suppressing the renin-angiotensin-aldosterone system in normotensive and hypertensive subjects.
    Blumenfeld JD; Sealey JE; Mann SJ; Bragat A; Marion R; Pecker MS; Sotelo J; August P; Pickering TG; Laragh JH
    Am J Hypertens; 1999 May; 12(5):451-9. PubMed ID: 10342782
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SGLT2 Inhibitors and the Diabetic Kidney.
    Fioretto P; Zambon A; Rossato M; Busetto L; Vettor R
    Diabetes Care; 2016 Aug; 39 Suppl 2():S165-71. PubMed ID: 27440829
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparing medication persistence among patients with type 2 diabetes using sodium-glucose cotransporter 2 inhibitors or glucagon-like peptide-1 receptor agonists in real-world setting.
    Rea F; Ciardullo S; Savaré L; Perseghin G; Corrao G
    Diabetes Res Clin Pract; 2021 Oct; 180():109035. PubMed ID: 34487757
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SGLT2 inhibitors and GLP1 agonists administered without metformin compared to other glucose-lowering drugs in patients with type 2 diabetes mellitus to prevent cardiovascular events: A systematic review.
    Escobar C; Barrios V; Cosín J; Gámez Martínez JM; Huelmos Rodrigo AI; Ortíz Cortés C; Torres Llergo J; Requeijo C; Solà I; Martínez Zapata MJ
    Diabet Med; 2021 Mar; 38(3):e14502. PubMed ID: 33368612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.